ÍøºìºÚÁÏ

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive…

Investigator

Ali Ataya

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator

Ali Ataya

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World ÍøºìºÚÁÏ Organization (WHO)…

Investigator

Ali Ataya

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All